Wall Street Predicts These 2 Sub-$5 Stocks Have More Than 200% Upside

: PRVB | Provention Bio, Inc. News, Ratings, and Charts

PRVB – Concerns over the Federal Reserve’s aggressive interest rate hikes to fight elevated inflation and the possibility of the economy tipping into a recession have fostered significant volatility in the market of late. Despite the market uncertainties, Wall Street analysts expect fundamentally sound sub-$5 stocks Provention Bio (PRVB) and Trevi (TRVI) to rally more than 200% in the near term. So, these stocks could be worth adding to your watchlist now. Read on….

Investors’ concerns over the Fed’s tightening monetary policy to combat persistently high inflation and the possibility of a recession have kept the stock market under tremendous pressure lately. Moreover, the Fed is expected to raise interest rates by 75 basis points next month, followed by 50 basis points in September.

Slowing growth and ongoing monetary tightening have weighed heavily on the market sentiment. However, experts believe it will be wise to stay invested, and running to the sidelines could lead to lower returns in the long term.

Despite the risk-off environment, Wall Street analysts expect low-priced stocks Provention Bio, Inc. (PRVB - Get Rating) and Trevi Therapeutics, Inc. (TRVI - Get Rating) to surge exponentially in the near term. So, we think these stocks could be ideal additions to your watchlist.

Provention Bio, Inc. (PRVB - Get Rating)

PRVB is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutics and solutions to intercept and prevent immune-mediated diseases.

The company’s product candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) for treating type one diabetes, PRV-3279 to treat lupus, and PRV-015 for gluten-free diet non-responding celiac disease. It has a market capitalization of $250.40 million.

In May, PRVB announced the FDA acceptance for review of Teplizumab Biologics License Application (BLA) resubmission for the delay of clinical type 1 diabetes in at-risk individuals. The FDA has assigned a user fee goal date of August 17, 2022.

“We are looking forward to sharing the progress of our commercial launch plans in anticipation of, if approved by FDA, bringing the first-ever disease-modifying therapy to the T1D clinical community and the patients and their families who have remained substantially underserved and frustrated for generations,” said Ashleigh Palmer, PRVB’s CEO & Co-Founder.

In the fiscal 2022 first quarter ended March 31, 2022, PRVB’s collaboration revenue amounted to $580,000, and its net interest income improved 103.6% from the year-ago value to $57,000. As of March 31, 2022, the company’s cash, cash equivalents, and marketable securities came in at $113.36 million, while its total assets stood at $122.46 million.

The $7.46 million consensus revenue estimate for the fiscal year 2022, ending December 2022, represents a 434.6% improvement from the previous year. Analysts expect PRVB’s EPS for fiscal 2023 (ending December 2023) to grow 38.1% year-over-year.

The stock has declined 30.4% year-to-date to close the last trading session at $3.91.

However, the 12-month median price target of $13.00 indicates a 232.5% potential upside. The price targets range from a low of $13.00 to a high of $16.00. Of the five Wall Street analysts that rated PRVB, four rated it Buy, while one rated it Hold.

Trevi Therapeutics, Inc. (TRVI - Get Rating)

TRVI is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of Haduvio to treat severe neurologically mediated conditions. The company has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. TRVI has a market capitalization of $94.78 million.

Yesterday, TRVI reported positive results from its Phase 2b/3 Pruritus Relief through Itch-Scratch Modulation (PRISM) trial of Haduvio in treating prurigo nodularis.

“This positive trial in prurigo nodularis, along with the highly statistically significant data from the interim analysis of our Phase 2 trial in IPF chronic cough that we presented earlier this year, further supports our belief that Haduvio could potentially benefit patients across a broad range of refractory chronic pruritic and cough conditions,” said Jennifer Good, President, and CEO of TRVI.

In April, TRVI completed a $55 million private placement. The gross proceeds might allow the company to fund the next phase of clinical development for Haduvio in chronic cough in IPF.

As of March 31, 2022, TRVI’s cash and cash equivalents came in at $29.11 million. In addition, the company’s working capital stood at $16.97 million, while its total assets came in at $30.39 million.

The consensus revenue estimate for the fiscal year 2022 (ending December 2022) represents an increase of 49.3% from the last year. TRVI’s shares have gained 255% over the past six months and 213.2% year-to-date to close the previous trading session at $2.45.

Each of the three Wall Street analysts that rated TRVI rated it Buy. The 12-month median price target of $10.00 indicates a 308.1% potential upside.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


PRVB shares were trading at $3.98 per share on Thursday morning, up $0.07 (+1.79%). Year-to-date, PRVB has declined -29.18%, versus a -20.27% rise in the benchmark S&P 500 index during the same period.


About the Author: Mangeet Kaur Bouns


Mangeet’s keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet’s looks to help retail investors understand the underlying factors before making investment decisions. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
PRVBGet RatingGet RatingGet Rating
TRVIGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Bear or Bull Market?

The S&P 500 is on the brink of bear market territory...but that outcome is not a given at this time. Steve Reitmeister shares insights gleaned from his 45 years of investing to shine a light on current conditions along with his top picks...

Read More Stories

More Provention Bio, Inc. (PRVB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PRVB News